Navigation Links
Dyadic International Introduces Advanced Biofuels Enzyme AlternaFuel® CMAX™ At World Biofuels Markets

JUPITER, Fla., March 22, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today the introduction of its most advanced biofuels enzyme, AlternaFuel® CMAX™, at the World Biofuels Markets exhibition in Rotterdam, The Netherlands.


Dyadic has recently completed its scale-up of AlternaFuel® CMAX™ which was derived from Dyadic's proprietary and patented C1 platform technology. AlternaFuel® CMAX™ has proven to be effective in converting multiple forms of biomass into fermentable sugars which is the critical step in the production of cellulosic ethanol and other advanced biofuels and biochemicals from non-food feedstocks.

The World Biofuels Markets is Europe's largest biofuels congress and exhibition, supporting the world's development and search for alternative energy sources. All attendees of the World Biofuels Markets are welcome to visit Dyadic's stand located at Booth #9 where Dyadic's leading scientists will be available to discuss specific applications of AlternaFuel® CMAX™.

Dyadic's President and CEO, Mark Emalfarb, will also be presenting the most recent data regarding the performance of AlternaFuel® CMAX™ at the World Biofuels Markets on Wednesday, March 23rd at the Biobased Chemicals session and on Thursday, March 24th at the Advanced Biofuels session.

Mr. Emalfarb stated, "Dyadic has always maintained that the best economic model for the efficient production of cellulosic sugars involves controlling the enzyme technology necessary for the on-site production of biofuels and biochemicals. The decision to make AlternaFuel® CMAX™ commercially available supports this goal by providing prospective partners with greater access to these unique enzymes in a ready-to-use formulation so that they can observe their performance and flexibility in demonstrations at their own facilities. We believe that this will not only provide additional revenue to Dyadic through product sales but will also provide greater opportunity for these customers to transition from purchasing these enzymes to ultimately manufacturing them on-site under license from Dyadic."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

For more information on AlternaFuel® CMAX™, please visit Dyadic's website at and contact:

Thomas M. O'Shaughnessy
Vice President Sales & Marketing
Dyadic International, Inc.
Phone: 561-743-8333

SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Reports 2010 Fiscal Year Financial Results
2. Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
3. Dyadic International Reports 2010 Third Quarter Financial Results
4. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
5. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
6. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
7. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
8. Dyadic International Engages The Abraham Group as Strategic Advisor
9. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
10. Dyadic International Strengthens Management Team
11. Dyadic International Extends Collaboration With The Scripps Research Institute
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
Breaking Biology News(10 mins):